Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02019810
Other study ID # 2013-003276-13
Secondary ID
Status Recruiting
Phase Phase 2
First received December 18, 2013
Last updated August 14, 2015
Start date October 2014
Est. completion date October 2016

Study information

Verified date August 2015
Source University Hospital, Grenoble
Contact Gilles Francony, MD
Phone 0033476766688
Is FDA regulated No
Health authority France:National Agency for Drugs and Medical Products Safety
Study type Interventional

Clinical Trial Summary

Severe traumatic brain injury with increased intracranial pressure can lead to decreased cerebral blood flow. Low cerebral blood flow is responsible for secondary lesions, leading to bad prognosis. It is not yet established whether increasing cardiac output in these patients can lead to an increase in cerebral blood flow, although there are some arguments in favor of this hypothesis. The aim of this study is to demonstrate that increasing cardiac output will improve cerebral blood flow in patients with severe traumatic injury and high cerebral pressure.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date October 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Traumatic brain injury (TBI) with pattern of oligemia (diastolic velocity < 30cm/second and/or mean velocity < 45cm/second measured with transcranial doppler or oxygen tissue pressure < 15mmHg)

- Closed traumatic brain injury

- Isolated TBI or polytraumatism

- Age between 18 and 65 years old

- Affiliated to a social security system

Exclusion Criteria:

- Instable episodes of high cerebral pressure

- Craniectomy

- High cerebral pressure without TBI

- No autoregulation

- Current hemorrhagic shock

- Chronic cardiac failure

- Chronic renal failure

- Hyperemia measured with transcranial doppler

- Short life expectancy

- Refused consent from the family

- Protected patients by the law

- Hypersensibility to one of the treatment or sulfites

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Brain Injuries
  • Severe Traumatic Brain Injury With High Cerebral Pressure

Intervention

Drug:
Norepinephrine

Dobutamine and norepinephrine


Locations

Country Name City State
France Grenoble University Hospital Grenoble

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean blood flow velocity Mean blood flow velocity averaged on the two middle cerebral arteries (right and left) measured one after after the initiation of treatment. Each velocity is calculated as an average on the 10 last minutes form continuous transcranial doppler monitoring After one hour of treatment No
Secondary Evolution of brain oxygenation under treatment Comparison of the brain tissue oxygenation curves (PbrO2) under treatment with and without dobutamine During one hour of treatment No
Secondary Dobutamine doses Dobutamine doses required to reach the same cerebral perfusion pressure than noradrenaline alone After one hour of treatment No
Secondary Resistivity index on renal doppler Measure of resistivity index on renal doppler after one hour of treatment with and without dobutamine After one hour of treatment No
Secondary Pulsatility index on renal doppler Measure of pulsatility index (PI) on renal doppler before and after one hour of treatment with and without dobutamine prediction of cerebral blood flow increase (patients with high initial renal PI) After one hour of treatment No
Secondary Cardiac output modifications Comparison of cardiac blood flow modifications under treatment for one hour with and without dobutamine During one hour of treatment No